Symbiotec Pharmalab Ltd
Symbiotec Pharmalab Ltd (SYMBIOTEC) is scheduled to report results on 21 Sept 2026. Symbiotec Pharmalab Ltd last reported results for the quarter ended Jun 2025, with sales of ₹203 crore and net profit of ₹30 crore. The stock last traded at ₹1,158, a market capitalisation of ₹7,444 crore, on a P/E of 64.5. Over the past 52 weeks the stock has ranged between ₹934 and ₹1,194. Figures are as of 21 Sept 2026 and are not real time.
Symbiotec Pharmalab Ltd share price and key metrics
- Current price
- ₹1,158
- Market cap
- ₹7,444 cr
- Stock P/E
- 64.5
- ROE
- 11.7%
- ROCE
- 13.0%
- Dividend yield
- 0.00%
- 52w high / low
- 1194/934
Metrics as of 21 Sept 2026. Not real time.
Track Symbiotec Pharmalab Ltd
Cruxal reads every Symbiotec Pharmalab Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Symbiotec Pharmalab Ltd growth and returns
- 10 Years
- %
- 5 Years
- 7%
- 3 Years
- 15%
- TTM
- 16%
- 10 Years
- %
- 5 Years
- -1%
- 3 Years
- 70%
- TTM
- 19%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- %
- 10 Years
- %
- 5 Years
- 12%
- 3 Years
- 13%
- Last Year
- 12%
Symbiotec Pharmalab Ltd quarterly results
| ₹ crore | Jun 2025 |
|---|---|
| Sales | 203 |
| Expenses | 145 |
| Operating profit | 58 |
| OPM % | 29% |
| Other income | 3 |
| Interest | 5 |
| Depreciation | 11 |
| Profit before tax | 45 |
| Tax % | 33% |
| Net profit | 30 |
| EPS (₹) | 46.99 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Symbiotec Pharmalab Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 633 | 682 | 567 | 716 | 752 | 869 |
| Operating profit | 195 | 131 | 70 | 172 | 203 | 239 |
| OPM % | 31% | 19% | 12% | 24% | 27% | 27% |
| Net profit | 123 | 78 | 23 | 100 | 97 | 110 |
| EPS (₹) | 112.72 | 70.89 | 21.48 | 91.49 | 151.98 | 17.51 |
TTM is the trailing twelve months to the most recent quarter.
Symbiotec Pharmalab Ltd balance sheet
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 11 | 11 | 11 | 11 | 11 | 13 |
| Reserves | 510 | 588 | 611 | 704 | 804 | 1,137 |
| Borrowings | 47 | 65 | 218 | 247 | 544 | 391 |
| Other liabilities | 200 | 152 | 151 | 326 | 220 | 240 |
| Total liabilities | 768 | 815 | 990 | 1,289 | 1,580 | 1,781 |
| Fixed assets | 261 | 280 | 299 | 448 | 438 | 1,120 |
| CWIP | 28 | 40 | 182 | 208 | 568 | 64 |
| Investments | 5 | 5 | 5 | 4 | 1 | 4 |
| Other assets | 474 | 490 | 504 | 628 | 572 | 592 |
| Total assets | 768 | 815 | 990 | 1,289 | 1,580 | 1,781 |
As reported by the company. Total assets equal total liabilities by construction.
Symbiotec Pharmalab Ltd cash flow
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 174 | 18 | 69 | 188 | 47 | 175 |
| Cash from investing | -96 | -32 | -220 | -206 | -307 | -227 |
| Cash from financing | -79 | 15 | 146 | 22 | 278 | 36 |
| Net cash flow | -1 | 1 | -5 | 3 | 19 | -16 |
| Free cash flow | 87 | -55 | -155 | -22 | -261 | -50 |
| CFO / operating profit | 112% | 36% | 124% | 129% | 40% | 99% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Symbiotec Pharmalab Ltd operating ratios
| Per year | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| ROCE % | — | 18% | 6% | 16% | 14% | 13% |
| Debtor days | 68 | 77 | 72 | 64 | 85 | 83 |
| Inventory days | 308 | 252 | 305 | 382 | 321 | 274 |
| Days payable | 155 | 91 | 110 | 259 | 109 | 160 |
| Cash conversion cycle | 221 | 238 | 267 | 187 | 298 | 197 |
| Working capital days | 86 | 121 | 107 | 76 | -3 | -22 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Symbiotec Pharmalab Ltd shareholding pattern
| % held | Sep 2026 |
|---|---|
| Promoters | 33.28% |
| FIIs | 21.08% |
| DIIs | 27.51% |
| Public | 18.12% |
| No. of shareholders | 4,27,730 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Symbiotec Pharmalab Ltd’s next results date?
Symbiotec Pharmalab Ltd’s next results are scheduled for 21 Sept 2026.
- Earnings resultsConsider and approve unaudited standalone and consolidated financial results for the quarter ended 30 June 2026
- Analyst meetQ1FY27 earnings conference call
See the full results calendar for every Indian company reporting in the next 30 days.
Cruxal coverage of Symbiotec Pharmalab Ltd
Symbiotec Pharmalab Ltd corporate filings
- Symbiotec Pharmalab Ltd files routine Regulation 30 press releaseCompany Updatelow impact
Cruxal's analysis: Symbiotec Pharmalab Ltd has submitted a press release under Regulation 30 of the SEBI…
Read the full analysis - Symbiotec Pharmalab Reports Q1 FY27 Results: Core API Growth Offset by Strategic Investments in New Business VerticalsCompany Updatehigh impact
Cruxal's analysis: Symbiotec Pharmalab Limited reported Q1 FY27 consolidated revenue of 218.2 crore, a 7%…
Read the full analysis - Symbiotec Pharmalab Reports Q1 FY2027 Financial Results Following Recent IPOBoard Meetingmedium impact
Cruxal's analysis: Symbiotec Pharmalab Limited has released its unaudited standalone and consolidated…
Read the full analysis - Symbiotec Pharmalab Schedules Q1FY27 Earnings Conference Call for September 22, 2026Company Updatelow impact
Cruxal's analysis: Symbiotec Pharmalab Limited has announced an earnings conference call to discuss its…
Read the full analysis - Symbiotec Pharmalab Limited: Promoters Re-create Share Pledges for Debenture SecurityInsider Trading / SASTlow impact
Cruxal's analysis: Symbiotec Pharmalab Limited has disclosed the re-creation of share pledges by various…
Read the full analysis - Symbiotec Pharmalab Limited schedules Board Meeting for September 21, 2026, to approve Q1 FY2027 financial resultsBoard Meetinglow impact
Cruxal's analysis: Symbiotec Pharmalab Limited has formally intimated the stock exchanges regarding a Board…
Read the full analysis - Symbiotec Pharmalab Limited: Promoter Group Pledges 34.93 Lakh Shares as Collateral for Debenture IssuanceInsider Trading / SASTmedium impact
Cruxal's analysis: Symbiotec Pharmalab Limited has disclosed that its promoter group, including Mr. Anil…
Read the full analysis - Symbiotec Pharmalab Ltd updates Code of Conduct under SEBI PIT RegulationsCompany Updatelow impact
Cruxal's analysis: Symbiotec Pharmalab Ltd has filed an update regarding its Code of Conduct in compliance…
Read the full analysis - Mirae Asset Mutual Fund increases stake in Symbiotec Pharmalab Ltd to 6.22% via open market acquisitionInsider Trading / SASTmedium impact
Cruxal's analysis: Symbiotec Pharmalab Ltd has witnessed a significant increase in institutional holding as…
Read the full analysis - Closure of trading window for the quarter ended June 30, 2026.Insider Trading / SASTlow impact
- Symbiotec Pharmalab Ltd files updated Code of Conduct under SEBI PIT RegulationsCompany Updatelow impact
Cruxal's analysis: Symbiotec Pharmalab Ltd has submitted an intimation regarding the amendment or adoption…
Read the full analysis - Symbiotec Pharmalab Ltd updates authorized personnel for materiality disclosures under SEBI Regulation 30(5)Company Updatelow impact
Cruxal's analysis: Symbiotec Pharmalab Ltd has submitted a routine disclosure under Regulation 30(5) of the…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.